Despite significant efforts in developing novel biomaterials to regenerate tissue, only a few of them have successfully reached clinical use. It has become clear that the next generation of biomaterials must be multifunctional. Smart biomaterials can respond to environmental or external stimuli, interact in a spatial-temporal manner, and trigger specific tissue/organism responses. In this study, how to fabricate the fabrication of novel 3D-printed and bioresorbable scaffolds, with embedded crystals that can convert near-infrared (NIR) light into visible light, is presented. It is demonstrated that these biophotonic scaffolds are not only bioactive and bioresorbable, but can also be promising as a platform for the controlled release or activation of photoactivated drugs locally and on demand, under illumination. The scaffolds are analyzed based on their up-conversion spectroscopic properties and their chemical stability in simulated body fluid. Furthermore, it is demonstrated that the up-conversion properties of the scaffolds are sufficient to release the signaling molecule nitric oxide (NO) and to photoisomerize the muscarinic ligand Phthalimide-Azo-Iperoxo (PAI), in a controlled manner, upon NIR light stimulus. Finally, to assess their biocompatibility for potential implantation, a preliminary study is conducted with human adipose stem cells cultured in contact with scaffolds. Live/dead assays, morphological analysis, CyQUANT analysis, and ion release measurements confirm that, despite some release of the upconverter crystals, the dissolution of the biophotonic materia and its dissolution by-products, are biocompatible. These findings highlight the potential of these bioresorbable biophotonic scaffolds for localized drug release in response to NIR light stimuli.
The field of G protein-coupled receptor (GPCR) research has greatly benefited from the spatiotemporal resolution provided by light controllable, i.e., photoswitchable ligands. Most of the developed tools have targeted the Rhodopsin-like family (Class A), the largest family of GPCRs. However, to date, all such Class A photoswitchable ligands were designed to act at the orthosteric binding site of these receptors. Herein, we report the development of the first photoswitchable allosteric modulators of Class A GPCRs, designed to target the M-1 muscarinic acetylcholine receptor. The presented benzyl quinolone carboxylic acid (BQCA) derivatives, Photo-BQCisA and Photo-BQCtrAns, exhibit complementary photopharmacological behavior and allow reversible control of the receptor using light as an external stimulus. This makes them valuable tools to further investigate M-1 receptor signaling and a proof of concept for photoswitchable allosteric modulators at Class A receptors.
Gamma aminobutyric acid type A receptors (GABA(A)Rs) play a key role in the mammalian central nervous system (CNS) as drivers of neuroinhibitory circuits, which are commonly targeted for therapeutic purposes with potentiator drugs. However, due to their widespread expression and strong inhibitory action, systemic pharmaceutical potentiation of GABA(A)Rs inevitably causes adverse effects regardless of the drug selectivity. Therefore, therapeutic guidelines must often limit or exclude clinically available GABA(A)R potentiators, despite their high efficacy, good biodistribution, and favorable molecular properties. One solution to this problem is to use drugs with light-dependent activity (photopharmacology) in combination with on-demand, localized illumination. However, a suitable light-activated potentiator of GABA(A)Rs has been elusive so far for use in wildtype mammals. We have met this need by developing azocarnil, a diffusible GABAergic agonist-potentiator based on the anxiolytic drug abecarnil that is inactive in the dark and activated by visible violet light. Azocarnil can be rapidly deactivated with green light and by thermal relaxation in the dark. We demonstrate that it selectively inhibits neuronal currents in hippocampal neurons in vitro and in the dorsal horns of the spinal cord of mice, decreasing the mechanical sensitivity as a function of illumination without displaying systemic adverse effects. Azocarnil expands the in vivo photopharmacological toolkit with a novel chemical scaffold and achieves a milestone toward future phototherapeutic applications to safely treat muscle spasms, pain, anxiety, sleep disorders, and epilepsy.
A problem of systemic pharmacotherapy is off-target activity, which causes adverse effects. Outstanding examples include neuroinhibitory medications like antiseizure drugs, which are used against epilepsy and neuropathic pain but cause systemic side effects. There is a need of drugs that inhibit nerve signals locally and on-demand without affecting other regions of the body. Photopharmacology aims to address this problem with light-activated drugs and localized illumination in the target organ. Here, we have developed photoswitchable derivatives of the widely prescribed antiseizure drug carbamazepine. For that purpose, we expanded our method of ortho azologization of tricyclic drugs to meta/para and to N-bridged diazocine. Our results validate the concept of ortho cryptoazologs (uniquely exemplified by Carbazopine-1) and bring to light Carbadiazocine (8), which can be photoswitched between 400-590 nm light (using violet LEDs and halogen lamps) and shows good drug-likeness and predicted safety. Both compounds display photoswitchable activity in vitro and in translucent zebrafish larvae. Carbadiazocine (8) also offers in vivo analgesic efficacy (mechanical and thermal stimuli) in a rat model of neuropathic pain and a simple and compelling treatment demonstration with non-invasive illumination.
Cookie Consent The IBEC website uses cookies and similar technologies to ensure the basic functionality of the site and for statistical and optimisation purposes. It also uses cookies to display content such as YouTube videos that use marketing cookies. This last category consists of tracking cookies: these make it possible for your online behaviour to be tracked. You consent to this by clicking on Accept. Also read our Privacy statement.
Read our cookie policy